Phase II trial of lenvatinib (LEN) at two starting doses plus everolimus (EVE) in patients (pts) with renal cell carcinoma (RCC): Results by independent imaging review (IIR) and prior immune checkpoint inhibition (ICI).

Sumanta K. Pal,Javier Puente,Daniel Yick Chin Heng,Hilary Glen,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Tudor Ciuleanu,Jae-Lyun Lee,Kaisa Sunela,Karen O'Hara,Terri A. Binder,Peng Lixian,Alan D. Smith,Sun Young Rha

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 7|浏览19

暂无评分

摘要

307Background: LEN 18 mg + EVE 5 mg is approved for advanced RCC following anti-angiogenic therapy. Study 218 was a phase II study evaluating LEN 14 mg vs LEN 18 mg, both in combination with EVE 5 ...

查看译文

关键词

Lenvatinib,Everolimus,Immune checkpoint,Renal cell carcinoma,Phases of clinical research,Oncology,Medicine,In patient,Internal medicine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要